Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Monster Beverage Corp (MNST) vs Merck & Co., Inc. (MRK) Price & Performance

Monster Beverage CorpTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Monster Beverage Corp vs Merck & Co., Inc. — how do they compare? Monster Beverage Corp trades at $93.91 (market cap $93.35B), while Merck & Co., Inc. trades at $125.97 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 3.3× Monster Beverage Corp's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.

MNSTMRK
Market Cap
$93.35B$307.25B
Sector
Consumer StaplesHealth
52-Week High
$99.94$129.52
52-Week Low
$58.75$77.60
Enterprise Value
$91.65B$350.66B
Dividend Yield
2.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Monster Beverage Corp

Monster Beverage (MNST) trades at $94.46, down 3.12% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.58 exceeding the $0.527 estimate, and maintains robust profitability with a net income margin of 23.11%. A 2-for-1 stock split is scheduled for August 2026, reflecting confidence in future growth.

The investment outlook is positive, driven by consistent earnings outperformance, international expansion, and product innovation. Risks include elevated valuation multiples (P/E of 46.11) and competitive pressures in the beverage sector. Analyst consensus is bullish with a $97.83 price target, suggesting modest upside from current levels.

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Monster Beverage Corp

Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.

Read more on MNST

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK